1 Multiple Sclerosis Drugs Market Overview 1.1 Product Overview and Scope of Multiple Sclerosis Drugs 1.2 Multiple Sclerosis Drugs Segment by Type 1.2.1 Global Multiple Sclerosis Drugs Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 Injectable Medications 1.2.3 Oral Medications 1.2.4 Others 1.3 Multiple Sclerosis Drugs Segment by Application 1.3.1 Global Multiple Sclerosis Drugs Sales Comparison by Application: (2021-2027) 1.3.2 Adults 1.3.3 Children 1.4 Global Multiple Sclerosis Drugs Market Size Estimates and Forecasts 1.4.1 Global Multiple Sclerosis Drugs Revenue 2016-2027 1.4.2 Global Multiple Sclerosis Drugs Sales 2016-2027 1.4.3 Multiple Sclerosis Drugs Market Size by Region: 2016 Versus 2021 Versus 2027 2 Multiple Sclerosis Drugs Market Competition by Manufacturers 2.1 Global Multiple Sclerosis Drugs Sales Market Share by Manufacturers (2016-2021) 2.2 Global Multiple Sclerosis Drugs Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Multiple Sclerosis Drugs Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Multiple Sclerosis Drugs Manufacturing Sites, Area Served, Product Type 2.5 Multiple Sclerosis Drugs Market Competitive Situation and Trends 2.5.1 Multiple Sclerosis Drugs Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Multiple Sclerosis Drugs Players Market Share by Revenue 2.5.3 Global Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Multiple Sclerosis Drugs Retrospective Market Scenario by Region 3.1 Global Multiple Sclerosis Drugs Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global Multiple Sclerosis Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America Multiple Sclerosis Drugs Market Facts & Figures by Country 3.3.1 North America Multiple Sclerosis Drugs Sales by Country 3.3.2 North America Multiple Sclerosis Drugs Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Multiple Sclerosis Drugs Market Facts & Figures by Country 3.4.1 Europe Multiple Sclerosis Drugs Sales by Country 3.4.2 Europe Multiple Sclerosis Drugs Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Multiple Sclerosis Drugs Market Facts & Figures by Region 3.5.1 Asia Pacific Multiple Sclerosis Drugs Sales by Region 3.5.2 Asia Pacific Multiple Sclerosis Drugs Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Multiple Sclerosis Drugs Market Facts & Figures by Country 3.6.1 Latin America Multiple Sclerosis Drugs Sales by Country 3.6.2 Latin America Multiple Sclerosis Drugs Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Multiple Sclerosis Drugs Market Facts & Figures by Country 3.7.1 Middle East and Africa Multiple Sclerosis Drugs Sales by Country 3.7.2 Middle East and Africa Multiple Sclerosis Drugs Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Multiple Sclerosis Drugs Historic Market Analysis by Type 4.1 Global Multiple Sclerosis Drugs Sales Market Share by Type (2016-2021) 4.2 Global Multiple Sclerosis Drugs Revenue Market Share by Type (2016-2021) 4.3 Global Multiple Sclerosis Drugs Price by Type (2016-2021) 5 Global Multiple Sclerosis Drugs Historic Market Analysis by Application 5.1 Global Multiple Sclerosis Drugs Sales Market Share by Application (2016-2021) 5.2 Global Multiple Sclerosis Drugs Revenue Market Share by Application (2016-2021) 5.3 Global Multiple Sclerosis Drugs Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Biogen 6.1.1 Biogen Corporation Information 6.1.2 Biogen Description and Business Overview 6.1.3 Biogen Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Biogen Multiple Sclerosis Drugs Product Portfolio 6.1.5 Biogen Recent Developments/Updates 6.2 Sanofi 6.2.1 Sanofi Corporation Information 6.2.2 Sanofi Description and Business Overview 6.2.3 Sanofi Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Sanofi Multiple Sclerosis Drugs Product Portfolio 6.2.5 Sanofi Recent Developments/Updates 6.3 Novartis 6.3.1 Novartis Corporation Information 6.3.2 Novartis Description and Business Overview 6.3.3 Novartis Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Novartis Multiple Sclerosis Drugs Product Portfolio 6.3.5 Novartis Recent Developments/Updates 6.4 Teva 6.4.1 Teva Corporation Information 6.4.2 Teva Description and Business Overview 6.4.3 Teva Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Teva Multiple Sclerosis Drugs Product Portfolio 6.4.5 Teva Recent Developments/Updates 6.5 Merck KGaA 6.5.1 Merck KGaA Corporation Information 6.5.2 Merck KGaA Description and Business Overview 6.5.3 Merck KGaA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Merck KGaA Multiple Sclerosis Drugs Product Portfolio 6.5.5 Merck KGaA Recent Developments/Updates 6.6 Bayer 6.6.1 Bayer Corporation Information 6.6.2 Bayer Description and Business Overview 6.6.3 Bayer Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Bayer Multiple Sclerosis Drugs Product Portfolio 6.6.5 Bayer Recent Developments/Updates 6.7 ACORDA 6.6.1 ACORDA Corporation Information 6.6.2 ACORDA Description and Business Overview 6.6.3 ACORDA Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021) 6.4.4 ACORDA Multiple Sclerosis Drugs Product Portfolio 6.7.5 ACORDA Recent Developments/Updates 6.8 Mallinckrodt 6.8.1 Mallinckrodt Corporation Information 6.8.2 Mallinckrodt Description and Business Overview 6.8.3 Mallinckrodt Multiple Sclerosis Drugs Sales, Revenue and Gross Margin (2016-2021) 6.8.4 Mallinckrodt Multiple Sclerosis Drugs Product Portfolio 6.8.5 Mallinckrodt Recent Developments/Updates 7 Multiple Sclerosis Drugs Manufacturing Cost Analysis 7.1 Multiple Sclerosis Drugs Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Multiple Sclerosis Drugs 7.4 Multiple Sclerosis Drugs Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Multiple Sclerosis Drugs Distributors List 8.3 Multiple Sclerosis Drugs Customers 9 Multiple Sclerosis Drugs Market Dynamics 9.1 Multiple Sclerosis Drugs Industry Trends 9.2 Multiple Sclerosis Drugs Growth Drivers 9.3 Multiple Sclerosis Drugs Market Challenges 9.4 Multiple Sclerosis Drugs Market Restraints 10 Global Market Forecast 10.1 Multiple Sclerosis Drugs Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Multiple Sclerosis Drugs by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Multiple Sclerosis Drugs by Type (2022-2027) 10.2 Multiple Sclerosis Drugs Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Multiple Sclerosis Drugs by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Multiple Sclerosis Drugs by Application (2022-2027) 10.3 Multiple Sclerosis Drugs Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Multiple Sclerosis Drugs by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Multiple Sclerosis Drugs by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Multiple Sclerosis Drugs Sales (K Units) Growth Rate Comparison by Type (2021-2027) Table 2. Global Multiple Sclerosis Drugs Sales (K Units) Comparison by Application (2021-2027) Table 3. Global Multiple Sclerosis Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Multiple Sclerosis Drugs Covered in This Study Table 5. Global Multiple Sclerosis Drugs Sales (K Units) of Key Manufacturers (2016-2021) Table 6. Global Multiple Sclerosis Drugs Sales Market Share by Manufacturers (2016-2021) Table 7. Global Multiple Sclerosis Drugs Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Multiple Sclerosis Drugs Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Multiple Sclerosis Drugs Average Price (USD/Unit) of Key Manufacturers (2016-2021) Table 10. Manufacturers Multiple Sclerosis Drugs Manufacturing Sites and Area Served Table 11. Manufacturers Multiple Sclerosis Drugs Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Multiple Sclerosis Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multiple Sclerosis Drugs as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Multiple Sclerosis Drugs Sales by Region (2016-2021) & (K Units) Table 16. Global Multiple Sclerosis Drugs Sales Market Share by Region (2016-2021) Table 17. Global Multiple Sclerosis Drugs Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Multiple Sclerosis Drugs Sales by Country (2016-2021) & (K Units) Table 19. North America Multiple Sclerosis Drugs Sales Market Share by Country (2016-2021) Table 20. North America Multiple Sclerosis Drugs Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2021) Table 22. Europe Multiple Sclerosis Drugs Sales by Country (2016-2021) & (K Units) Table 23. Europe Multiple Sclerosis Drugs Sales Market Share by Country (2016-2021) Table 24. Europe Multiple Sclerosis Drugs Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Multiple Sclerosis Drugs Sales by Region (2016-2021) & (K Units) Table 27. Asia Pacific Multiple Sclerosis Drugs Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Multiple Sclerosis Drugs Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Multiple Sclerosis Drugs Revenue Market Share by Region (2016-2021) Table 30. Latin America Multiple Sclerosis Drugs Sales by Country (2016-2021) & (K Units) Table 31. Latin America Multiple Sclerosis Drugs Sales Market Share by Country (2016-2021) Table 32. Latin America Multiple Sclerosis Drugs Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Multiple Sclerosis Drugs Sales by Country (2016-2021) & (K Units) Table 35. Middle East and Africa Multiple Sclerosis Drugs Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Multiple Sclerosis Drugs Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Multiple Sclerosis Drugs Revenue Market Share by Country (2016-2021) Table 38. Global Multiple Sclerosis Drugs Sales (K Units) by Type (2016-2021) Table 39. Global Multiple Sclerosis Drugs Sales Market Share by Type (2016-2021) Table 40. Global Multiple Sclerosis Drugs Revenue (Million US$) by Type (2016-2021) Table 41. Global Multiple Sclerosis Drugs Revenue Share by Type (2016-2021) Table 42. Global Multiple Sclerosis Drugs Price (USD/Unit) by Type (2016-2021) Table 43. Global Multiple Sclerosis Drugs Sales (K Units) by Application (2016-2021) Table 44. Global Multiple Sclerosis Drugs Sales Market Share by Application (2016-2021) Table 45. Global Multiple Sclerosis Drugs Revenue (Million US$) by Application (2016-2021) Table 46. Global Multiple Sclerosis Drugs Revenue Share by Application (2016-2021) Table 47. Global Multiple Sclerosis Drugs Price (USD/Unit) by Application (2016-2021) Table 48. Biogen Corporation Information Table 49. Biogen Description and Business Overview Table 50. Biogen Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 51. Biogen Multiple Sclerosis Drugs Product Table 52. Biogen Recent Developments/Updates Table 53. Sanofi Corporation Information Table 54. Sanofi Description and Business Overview Table 55. Sanofi Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 56. Sanofi Multiple Sclerosis Drugs Product Table 57. Sanofi Recent Developments/Updates Table 58. Novartis Corporation Information Table 59. Novartis Description and Business Overview Table 60. Novartis Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 61. Novartis Multiple Sclerosis Drugs Product Table 62. Novartis Recent Developments/Updates Table 63. Teva Corporation Information Table 64. Teva Description and Business Overview Table 65. Teva Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 66. Teva Multiple Sclerosis Drugs Product Table 67. Teva Recent Developments/Updates Table 68. Merck KGaA Corporation Information Table 69. Merck KGaA Description and Business Overview Table 70. Merck KGaA Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 71. Merck KGaA Multiple Sclerosis Drugs Product Table 72. Merck KGaA Recent Developments/Updates Table 73. Bayer Corporation Information Table 74. Bayer Description and Business Overview Table 75. Bayer Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 76. Bayer Multiple Sclerosis Drugs Product Table 77. Bayer Recent Developments/Updates Table 78. ACORDA Corporation Information Table 79. ACORDA Description and Business Overview Table 80. ACORDA Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 81. ACORDA Multiple Sclerosis Drugs Product Table 82. ACORDA Recent Developments/Updates Table 83. Mallinckrodt Corporation Information Table 84. Mallinckrodt Description and Business Overview Table 85. Mallinckrodt Multiple Sclerosis Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 86. Mallinckrodt Multiple Sclerosis Drugs Product Table 87. Mallinckrodt Recent Developments/Updates Table 88. Production Base and Market Concentration Rate of Raw Material Table 89. Key Suppliers of Raw Materials Table 90. Multiple Sclerosis Drugs Distributors List Table 91. Multiple Sclerosis Drugs Customers List Table 92. Multiple Sclerosis Drugs Market Trends Table 93. Multiple Sclerosis Drugs Growth Drivers Table 94. Multiple Sclerosis Drugs Market Challenges Table 95. Multiple Sclerosis Drugs Market Restraints Table 96. Global Multiple Sclerosis Drugs Sales Forecast by Type (2022-2027) & (K Units) Table 97. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Type (2022-2027) Table 98. Global Multiple Sclerosis Drugs Revenue Forecast by Type (2022-2027) & (US$ Million) Table 99. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Type (2022-2027) Table 100. Global Multiple Sclerosis Drugs Sales Forecast by Application (2022-2027) & (K Units) Table 101. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Application (2022-2027) Table 102. Global Multiple Sclerosis Drugs Revenue Forecast by Application (2022-2027) & (US$ Million) Table 103. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Application (2022-2027) Table 104. Global Multiple Sclerosis Drugs Sales Forecast by Region (2022-2027) & (K Units) Table 105. Global Multiple Sclerosis Drugs Sales Market Share Forecast by Region (2022-2027) Table 106. Global Multiple Sclerosis Drugs Revenue Forecast by Region (2022-2027) & (US$ Million) Table 107. Global Multiple Sclerosis Drugs Revenue Market Share Forecast by Region (2022-2027) Table 108. Research Programs/Design for This Report Table 109. Key Data Information from Secondary Sources Table 110. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Multiple Sclerosis Drugs Figure 2. Global Multiple Sclerosis Drugs Market Share by Type in 2020 & 2027 Figure 3. Injectable Medications Product Picture Figure 4. Oral Medications Product Picture Figure 5. Others Product Picture Figure 6. Global Multiple Sclerosis Drugs Market Share by Application in 2020 & 2027 Figure 7. Adults Figure 8. Children Figure 9. Global Multiple Sclerosis Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 10. Global Multiple Sclerosis Drugs Market Size 2016-2027 (US$ Million) Figure 11. Global Multiple Sclerosis Drugs Sales 2016-2027 (K Units) Figure 12. Global Multiple Sclerosis Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 13. Multiple Sclerosis Drugs Sales Share by Manufacturers in 2020 Figure 14. Global Multiple Sclerosis Drugs Revenue Share by Manufacturers in 2020 Figure 15. The Global 5 and 10 Largest Multiple Sclerosis Drugs Players: Market Share by Revenue in 2020 Figure 16. Multiple Sclerosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 17. Global Multiple Sclerosis Drugs Sales Market Share by Region (2016-2021) Figure 18. Global Multiple Sclerosis Drugs Sales Market Share by Region in 2020 Figure 19. Global Multiple Sclerosis Drugs Revenue Market Share by Region (2016-2021) Figure 20. Global Multiple Sclerosis Drugs Revenue Market Share by Region in 2020 Figure 21. U.S. Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 22. Canada Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 23. Germany Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 24. France Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. U.K. Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. Italy Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. Russia Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. China Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. Japan Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. South Korea Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. India Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. Australia Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. Taiwan Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. Indonesia Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Thailand Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Malaysia Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Philippines Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Vietnam Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Mexico Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Brazil Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Argentina Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Turkey Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Saudi Arabia Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. U.A.E Multiple Sclerosis Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Sales Market Share of Multiple Sclerosis Drugs by Type (2016-2021) Figure 46. Sales Market Share of Multiple Sclerosis Drugs by Application (2016-2021) Figure 47. Sales Market Share of Multiple Sclerosis Drugs by Application in 2020 Figure 48. Revenue Share of Multiple Sclerosis Drugs by Application (2016-2021) Figure 49. Revenue Share of Multiple Sclerosis Drugs by Application in 2020 Figure 50. Manufacturing Cost Structure of Multiple Sclerosis Drugs Figure 51. Manufacturing Process Analysis of Multiple Sclerosis Drugs Figure 52. Multiple Sclerosis Drugs Industrial Chain Analysis Figure 53. Channels of Distribution Figure 54. Distributors Profiles Figure 55. Bottom-up and Top-down Approaches for This Report Figure 56. Data Triangulation Figure 57. Key Executives Interviewed

Biogen Sanofi Novartis Teva Merck KGaA Bayer ACORDA Mallinckrodt